



DN IVD 925

C9C

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Loic Foulon et al.
Patent No.: 5,994,350
Granted: November 30, 1999
Serial No.: 09/051,900
Filing Date: April 17, 1998
Group Art Unit: 1613
For: 3-Spiro-Indolin-2-One Derivatives As
Vasopressin And/Or Oxytocin Receptor Ligands

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

CERTIFICATE UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence is
being deposited on the date indicated below
with the United States Postal Service as first
class mail addressed to:
Commissioner for Patents,
Washington, D.C. 20231

Name

Date

Michael D. Oben

March 22, 2001

CERTIFICATE

APR 05 2001

OF CORRECTION**APPROVED**

JUN 2 2001

FOR THE COMMISSIONER

Christa Joyce
FOR THE COMMISSIONER

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.322

It has been discovered that certain printer's errors, as specified in the attached Certificate of Correction form (Form PTO-1050) submitted herewith in duplicate, occur in the above-identified U.S. Patent.

The errors found in the patent and the corresponding location in the application are as follows:

Column 6, line 1 to Column 7, line 4, should be deleted as this is a duplicate of the information that already occurs at Column 5, line 4 to Column 5, line 66 and from Column 7, line 5 to Column 7, line 11.


Column 53, line 66 (application claim 8 as amended under Article 34), "(IA)" should read as --(IIA)--.

Column 56, lines 13-14 (application claim 18 as amended under Article 34), "[4-(2-morpholinoethyloxy)]" should read as --[4-(2-morpholinoethyloxy)]--.

It is believed that these errors warrant the issuance of a Certificate of Correction, and in accordance with 37 C.F.R. §1.322, it is respectfully requested that a Certificate of Correction be issued and forwarded to the address below.

Respectfully submitted,

Date: *March 22, 2001*

A handwritten signature in cursive script, reading "Michael D. Alexander", written over a horizontal line.

Michael D. Alexander
Reg. No. 36,080

Address:
Sanofi-Synthelabo Inc.
9 Great Valley Parkway
P.O. Box 3026
Malvern, PA 19355
Telephone: (610) 889-8802
Fax: (610) 889-8799

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also Form PTO -1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : **5,994,350**
DATED : **November 30, 1999**
INVENTOR(S): **Loic Foulon, Georges Garcia, Claudine Serradeil-Le Gal and
Gerard Valette**

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below.

Column 6, line ²~~4~~ to Column 7, line 4 should be deleted as this is a duplicate of the information that already occurs at Column 5, line 4 to Column 5, line 66 and from Column 7, line 5 to Column 7, line 11.

Column 53, line 66, "(IA)" should read as --(IIA)--.

Column 56, lines 13-14, "[~~(2-morpholinoethyloxy)~~]" should read as --[4-(2-morpholinoethyloxy)--.

MAILING ADDRESS OF SENDER:

Sanofi-Synthelabo Inc.
Patent Department
9 Great Valley Parkway
P.O. Box 3026
Malvern, PA 19355

PATENT NO. 5,994,350

No. of additional copies



Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 29231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also Form PTO -1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : **5,994,350**
DATED : **November 30, 1999**
INVENTOR(S): **Loic Foulon, Georges Garcia, Claudine Serradeil-Le Gal and
Gerard Valette**

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below.

Column 6, line 1 to Column 7, line 4 should be deleted as this is a duplicate of the information that already occurs at Column 5, line 4 to Column 5, line 66 and from Column 7, line 5 to Column 7, line 11.

Column 53, line 66, "(IA)" should read as --(IIA)--.

Column 56, lines 13-14, "[(2-morpholinoethyloxy)" should read as --[4-(2-morpholinoethyloxy)--.

MAILING ADDRESS OF SENDER:

Sanofi-Synthelabo Inc.
Patent Department
9 Great Valley Parkway
P.O. Box 3026
Malvern, PA 19355

PATENT NO. 5,994,350

No. of additional copies



Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.